1stOncology™: Cancer Intelligence Service – Page 9327 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

On September 15, 2021 NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome to address disease at the base level using a new class of precision genetic medicines, reported that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 20 – 23 (Press release, NeuBase Therapeutics, SEP 15, 2021, View Source [SID1234587756]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Date: Tuesday, September 21st
Time: 3:45 p.m. ET
Location: Webcast Link – or at the company’s website (click here)

aTyr Pharma Announces Proposed Public Offering of Common Stock

On September 15, 2021 aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, reported that it has commenced an underwritten public offering of shares of its common stock (Press release, aTyr Pharma, SEP 15, 2021, View Source [SID1234587755]). In addition, aTyr expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of the shares to be sold in the offering are to be sold by aTyr. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Piper Sandler and RBC Capital Markets are acting as joint book-running managers for the offering.

The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, filed by aTyr that was declared effective by the Securities and Exchange Commission ("SEC") on August 23, 2021. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. Copies of the preliminary prospectus supplement, when available, and the accompanying prospectus relating to the offering may be obtained by contacting Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at [email protected]; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, New York 10281, by telephone at (877) 822-4089 or by email at [email protected]. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

DURECT Corporation Fireside Chat at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit

On September 15, 2021 DURECT Corporation (Nasdaq: DRRX) reported that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc (Press release, DURECT, SEP 15, 2021, https://investors.durect.com/news-releases/news-release-details/durect-corporation-fireside-chat-oppenheimers-fall-healthcare [SID1234587754]).

Presentation details are as follows:

Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit

Date:

September 22, 2021

Time:

2:05 P.M. to 2:45 P.M. Eastern Standard Time

Format:

Fireside chat hosted by Francois Brisebois

Webcast:

View Source

The webcast link of the presentation will also be available by accessing DURECT’s homepage at www.durect.com and clicking on "Event Calendar" under the "Investors" section.

Management will also be available for virtual 1×1 meetings during the conference. If you would like to request a meeting, please contact Oppenheimer directly.

IntelGenx Receives U.S.$6 Million in Additional Loans from atai Life Sciences and Conditional Approval to Graduate to Toronto Stock Exchange

On September 15, 2021 IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the "Company") reported that its wholly-owned subsidiary, IntelGenx Corp. ("IntelGenx"), has entered into an amended and restated secured loan agreement (the "Loan Agreement") with atai Life Sciences ("atai") pursuant to which atai has made two additional term loans available to IntelGenx in the amount of U.S.$3,000,000 each (the "New Loans"), which will mature on January 5, 2024 (Press release, IntelGenx, SEP 15, 2021, View Source [SID1234587753]). The New Loans will be made on January 7, 2022 and January 6, 2023, respectively, subject to the satisfaction of customary conditions. The Loan Agreement also extends the maturity date for the current loans, in an aggregate amount of U.S.$2,500,000, to January 5, 2024. The obligations under the New Loans are guaranteed by the Company.

The Company also announces that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to graduate from the TSX Venture Exchange and list its shares of common stock (the "Common Shares"), its 8% convertible debentures with a maturity date of June 30, 2022, and its share purchase warrants expiring on February 11, 2023, on the TSX. Final approval of the listing is subject to the Company meeting certain requirements of the TSX. The Company will make a further announcement once the TSX has issued a bulletin confirming the date on which trading on the TSX will commence. In connection with the listing on the TSX, the Company will apply to voluntarily delist its Common Shares, debentures and warrants from the TSX Venture Exchange to be effective as of the date the Common Shares, debentures and warrants commence trading on the TSX.

"Graduating to the TSX will be a significant milestone for our Company coming as a result of, among other recent accomplishments, our transformative strategic partnership with atai," commented Dr. Horst G. Zerbe, CEO of IntelGenx. "The TSX is Canada’s premier stock exchange and this should increase the visibility of IntelGenx to a broader and more diverse range of institutional investors, both at home and abroad."

PACIRA BIOSCIENCES REPORTS PRELIMINARY NET PRODUCT SALES OF $42.3 MILLION FOR AUGUST 2021

On September 15, 2021 Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, reported preliminary unaudited net product sales. EXPAREL (bupivacaine liposome injectable suspension) net product sales increased 15 percent to $41.4 million for the month of August 2021, compared with $36.1 million for the prior year (Press release, Pacira Pharmaceuticals, SEP 15, 2021, View Source [SID1234587752]). Net product sales of iovera° increased 13 percent to $0.9 million for the month of August 2021, compared with $0.8 million for the prior year. EXPAREL average daily sales for the month of August 2021 were 109 percent of August 2020. The company reports average daily growth rates for EXPAREL to account for differences in the number of selling days per reporting period. EXPAREL selling days were 22 in August 2021 and 21 in August 2020.

"We continue to solidify our leadership position in opioid-sparing pain management with EXPAREL now having treated more than nine million patients since launch with penetration increasing across all target market segments," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "EXPAREL utilization continues to significantly outpace the recovery of the elective surgery market, which is facing additional pandemic-related challenges this summer with regional surges in delta variant cases, staffing shortages, and surgical fatigue from care teams addressing significant procedure backlogs. We expect these variables to subside and the fourth quarter to reflect improving market dynamics."

"From a competitive standpoint, we have not experienced impact from new market entrants and EXPAREL remains extremely well positioned given its broad efficacy label that spans infiltration, field blocks and brachial plexus nerve block. In addition, a pristine safety profile and proven ability to reliably facilitate surgical migration to outpatient sites of care continue to be hallmarks of EXPAREL adoption across pediatric and adult settings. Looking ahead, we remain confident in our ability to achieve our five-year objectives and deliver topline annual growth in the high teens with operating margins that exceed 50 percent by the end of our planning period," continued Mr. Stack.

The company’s net product sales were negatively impacted by the COVID-19 pandemic in 2020 due to the significant postponement or suspension in the scheduling of elective surgical procedures resulting from public health guidance and government directives. Elective surgery restrictions began to lift on a state-by-state basis in April 2020, allowing EXPAREL sales to return to year-over-year growth in June 2020. However, while many restrictions have since eased and COVID-19 vaccines become more widely available and administered to the general public, it is still unclear how long it will take the elective surgery market to normalize, or if restrictions on elective procedures will recur due to COVID-19 variant strains or otherwise.

To provide greater transparency, the company is reporting monthly intra-quarter unaudited net product sales until it has gained enough visibility around the impacts of COVID-19. The company is also providing weekly EXPAREL utilization and elective surgery data within its investor presentation, which is accessible at investor.pacira.com. The financial information included in this press release is preliminary, unaudited, and subject to adjustment. It does not present all information necessary for an understanding of the company’s financial results for the third quarter or full year 2021.